Comparing two blood thinners for atrial fibrillation and heart disease
Part of Heart & circulation clinical trials.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old.
- You have atrial fibrillation (irregular heartbeat) that requires a blood thinner, and you have a higher risk of stroke (score of 2 or more on the CHA2DS2-VASc scale).
- You also have coronary artery disease. This can be a history of a heart procedure like a stent (PCI) or bypass surgery, or a narrowing of at least 50% in a major heart artery.
- You must not have severe kidney problems (dialysisor very low kidney function) or active major bleeding.
- You are not pregnant or breastfeeding.
- You can give informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to manage blood-thinning medications after a successful atrial fibrillation ablation, specifically for people who also have a heart stent. It aims to find the safest and most effective strategy to prevent strokes and bleeding.
This trial tests whether a lower dose of the blood thinner edoxaban can safely prevent another stroke in people aged 80 or older who have atrial fibrillation (an irregular heartbeat) and have already had a stroke or mini-stroke. It may be an option for those at higher risk of bleeding.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
This study compares two blood thinners, edoxaban and apixaban, to see how they affect new brain lesions seen on MRI in people who have had a stroke and also have atrial fibrillation. It aims to find which might be safer for preventing future brain damage.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.